Detalhe da pesquisa
1.
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up.
Clin Infect Dis
; 78(1): 164-171, 2024 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37773767
2.
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Clin Infect Dis
; 75(6): 1006-1013, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028659
3.
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Clin Infect Dis
; 75(8): 1307-1314, 2022 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243494
4.
Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.
medRxiv
; 2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37398252
5.
Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion.
PLoS One
; 17(11): e0276457, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36355658